Oct 15 (Reuters) - Merck & Co Inc MRK.N :
* HEALTH CANADA APPROVES KEYTRUDA (PEMBROLIZUMAB) AS FIRST-LINE TREATMENT FOR PATIENTS WITH METASTATIC OR UNRESECTABLE RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Oct 15 (Reuters) - Merck & Co Inc MRK.N :
* HEALTH CANADA APPROVES KEYTRUDA (PEMBROLIZUMAB) AS FIRST-LINE TREATMENT FOR PATIENTS WITH METASTATIC OR UNRESECTABLE RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA